PFIZER Limited
NSE Symbol PFIZER
REVIEW OF RESULTS OF Q3
Pfizer Ltd has declared the results for the 3rd Qtr ending 31.08.2010. It’s accounting year is Dec – Nov.
Net Sales for q/e Aug,2010 is Rs.225.61 Cr. At this rate, likely sales for Y/e Nov,2010 will be Rs.866.16 Cr – compared to Rs.771.60 for previous year (Non-consolidated). For this purpose Q1+Q2+Q3 are taken and for Q4, same level as Q3 is assumed.
On the same logic, Net Profit for Q3 is Rs.42.48 Cr and likely profit for Y/e Nov,2010 is Rs.162.10 Cr – against Rs.137.18 Cr for previous year.
Basic EPS for Q3 is Rs.14.24 (Rs.11.63 for Q2 + Rs.14.23 for Q1) and the likely EPS for the Y/E Nov,2010 is Rs.54.34 – compared to Rs.45.97 for preceding Year.
Current Market Price is Rs.1117.The PE ratio is around 20.6.
The company’s amalgamation was done with Du Chem Labs. But, these results are non-consolidated results only. The results are evidently much better than the results of Y/e Nov,2009 and reflect considerable progress over the previous year.
RESULTS IN FIGURES:
| PFIZER | 2010 Aug | 2010 May | 2010 Feb | Q1+Q2+ Q3 +(Q3 for Q4) | |
| Net Sales | 22561 | 21233 | 20261 | 86616 | 77160 |
| Other Operating Income | 1109 | 1112 | 494 | 3824 | 2437 |
| SIT & WIP | -1517 | -1234 | 1156 | -3112 | 961 |
| Raw Materials | 6501 | 5720 | 4022 | 22744 | 19867 |
| Purchase of Traded Goods | 2042 | 2932 | 2604 | 9620 | 7906 |
| Employees Cost | 4616 | 4973 | 2736 | 16941 | 12388 |
| Depreciation | 249 | 222 | 229 | 949 | 829 |
| Other Expenditure | 6796 | 6333 | 5064 | 24989 | 22651 |
| Total Expenditure | 18687 | 18946 | 15811 | 72131 | 64602 |
| Profit from Operations | 4983 | 3399 | 4944 | 18309 | 14995 |
| Other Income | 1591 | 2148 | 1548 | 6878 | 7101 |
| Profit A I BB EI | 6574 | 5547 | 6492 | 25187 | 22096 |
| Exceptional Items | 147 | 124 | - | 271 | 1092 |
| Profit before tax | 6427 | 5423 | 6492 | 24769 | 21004 |
| Tax expense | 2179 | 1954 | 2247 | 8559 | 7286 |
| Net Profit after tax | 4248 | 3469 | 4245 | 16210 | 13718 |
| Net Profit | 4248 | 3469 | 4245 | 16210 | 13718 |
| Dividend (%) | - | - | - | 125 | |
| Face Value .Rs | 10 | 10 | 10 | 10 | 10 |
| Paid Up Equity | 2984 | 2984 | 2984 | 2984 | 2984 |
| Basic EPS | 14.24 | 11.63 | 14.23 | 54.34 | 45.97 |
| Public holding (%) | 29.25 | 29.25 | 29.25 | 29.25 | 29.25 |
ANNOUNCEMENTS
TO THE EXCHANGE
06-10-2010 Pfizer Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-AUG-2010 as follows: Net Sales of Rs. 22561 lacs for quarter ending on 31-AUG-2010 against Rs. 20484 lacs for the quarter ending on 31-AUG-2009. Net Profit / (Loss) of Rs. 4248 lacs for the quarter ending on 31-AUG-2010 against Rs. 4115 lacs for the quarter ending on 31-AUG-2009. -
12-07-2010 Pfizer Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAY-2010 as follows: Net Sales of Rs. 21233 lacs for quarter ending on 31-MAY-2010 against Rs. 18585 lacs for the quarter ending on 31-MAY-2009. Net Profit / (Loss) of Rs. 3469 lacs for the quarter ending on 31-MAY-2010 against Rs. 3129 lacs for the quarter ending on 31-MAY-2009.
19-05-2010 News Verification : The media had reports that Pfizer Limited may buy a controlling stake in Piramal Healthcare Limited. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Pfizer Limited has vide its letter inter-alia stated," We wish to inform you that as a policy we do not comment on market rumours and speculations."
25-02-2010 Pfizer Ltd. has informed the Exchange that the Board of Directors at its meeting held on February 25, 2010, recommended a Dividend of Rs. 12.50 per Equity Share of Rs.10/- each (125%) for the financial year ended November 30, 2009.
25-02-2010 Pfizer Ltd. has informed the Exchange regarding the consolidated Results for the year ended on 30-NOV-2009 as follows: Net Sales of Rs. 77227 lacs for year ending on 30-NOV-2009 against Rs. 68170 lacs for the year ending on 30-NOV-2008. Net Profit / (Loss) of Rs. 13712 lacs for the year ending on 30-NOV-2009 against Rs. 29958 lacs for the year ending on 30-NOV-2008.
BOARD MEETINGS
19-03-2010 The Company proposes to reconsider the audited Financial Results of the merged entity i.e. Pfizer Ltd. and Duchem Laboratories Ltd. A meeting of the Board of Directors of Pfizer Ltd. would be held on March 19, 2010, to reconsider and approve the Annual Financial Results of the merged entity with a view to give effect to the Court order.
* * * E N D * * *
No comments:
Post a Comment